The estimated Net Worth of David D O'toole is at least $1.1 Million dollars as of 30 May 2024. Mr toole owns over 1,000 units of Opiant Pharmaceuticals Inc stock worth over $407,507 and over the last 12 years he sold OPNT stock worth over $73,530. In addition, he makes $618,950 as Chief Financial Officer at Opiant Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr Toole OPNT stock SEC Form 4 insiders trading
Mr has made over 27 trades of the Opiant Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of OPNT stock worth $8,900 on 30 May 2024.
The largest trade he's ever made was buying 10,000 units of Opiant Pharmaceuticals Inc stock on 4 March 2013 worth over $20,200. On average, Mr trades about 1,345 units every 112 days since 2012. As of 30 May 2024 he still owns at least 19,734 units of Opiant Pharmaceuticals Inc stock.
You can see the complete history of Mr toole stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. David D. O'Toole biography
David D. O'Toole is the Chief Financial Officer at Opiant Pharmaceuticals Inc.
What is the salary of Mr Toole?
As the Chief Financial Officer of Opiant Pharmaceuticals Inc, the total compensation of Mr Toole at Opiant Pharmaceuticals Inc is $618,950. There are 4 executives at Opiant Pharmaceuticals Inc getting paid more, with Roger Crystal having the highest compensation of $5,413,730.
How old is Mr Toole?
Mr Toole is 62, he's been the Chief Financial Officer of Opiant Pharmaceuticals Inc since . There are 3 older and 6 younger executives at Opiant Pharmaceuticals Inc. The oldest executive at Opiant Pharmaceuticals Inc is Michael Sinclair, 77, who is the Executive Chairman of the Board.
What's Mr Toole's mailing address?
David's mailing address filed with the SEC is 28159 AVENUE STANFORD, SUITE 220 - AVITA MEDICAL, VALENCIA, CA, 91355.
Insiders trading at Opiant Pharmaceuticals Inc
Over the last 21 years, insiders at Opiant Pharmaceuticals Inc have traded over $16,027,532 worth of Opiant Pharmaceuticals Inc stock and bought 199,545 units worth $2,080,156 . The most active insiders traders include Craig A Collard, Marc A Cohen, and Alain J Cohen. On average, Opiant Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $159,046. The most recent stock trade was executed by Roger Crystal on 27 January 2023, trading 1,358 units of OPNT stock currently worth $27,513.
What does Opiant Pharmaceuticals Inc do?
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
What does Opiant Pharmaceuticals Inc's logo look like?
Complete history of Mr toole stock trades at Codexis, Medicinova Inc, Opiant Pharmaceuticals Inc, and AVITA Medical Inc
Opiant Pharmaceuticals Inc executives and stock owners
Opiant Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Roger Crystal,
President, Chief Executive Officer, Director -
Michael Sinclair,
Executive Chairman of the Board -
Dr. Roger Crystal,
Pres, CEO & Director -
Dr. Phil Skolnick D.Sc. (hon), Ph.D.,
Chief Scientific Officer -
David D. O'Toole,
Chief Financial Officer -
Michael Porter,
IR Contact Officer -
Richard Daly,
Independent Director -
Craig Collard,
Independent Director -
Thomas Thomas,
Director -
Gabrielle Silver,
Director -
Ann MacDougall,
Director -
Aziz Mottiwala,
Chief Commercial Officer -
Rahsaan Thompson,
General Counsel -
Phil Skolnick,
Chief Scientific Officer -
Arvind Agrawal,
Executive Vice President - Medical Affairs -
David O'Toole,
Chief Financial Officer -
Matthew R. Ruth,
Chief Commercial Officer -
Dr. Mark Heath Ellison Ph.D.,
Chief Devel. Officer -
Brian Gorman,
EVP Corp. Devel. & Gen. Counsel -
Ben Atkins,
VP of Communications & Investor Relations -
Matthew R. Ruth,
Chief Commercial Officer -
Ronald W Kaiser,
Director -
Melvin Iii Wesley,
Chief Financial Officer -
William F Stasior,
Director -
Steven G Finn,
Director -
Joseph W Kuhn,
VP & Chief Financial Officer -
Alain J Cohen,
President & Chief Tech Officer -
Marc A Cohen,
Chairman, CEO, Treas, & Sec -
Brian Gorman,
-
Mark Jason Heath Ellison,
Chief Development Officer -
Masuoka K. Lorianne,
Director